Background Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid ...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for ...

When patients undergo general anesthesia, doctors can choose among several drugs. Although each of these drugs acts on ...

This framework was applied to neural recordings from animals receiving one of the three anesthetics—propofol, ketamine, and dexmedetomidine.

Explore NMDA receptor modulation and its critical role in neuronal development and cognitive functions like learning and ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients ...

In recent years, a drug called ketamine has attracted attention because it can reduce depressive symptoms very quickly. Unlike traditional antidepressants, which may take weeks to work, ketamine can ...

Researchers used a novel PET tracer to visualize how ketamine alters AMPA receptor distribution in the brains of patients ...

Major depressive disorder (MDD) is a major global health problem and one of the leading causes of disability. About 30% of people diagnosed with ...

A new brain-imaging study has revealed how ketamine produces its fast antidepressant effects in people with ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...